GlaxoSmithKline Consumer Healthcare Pakistan Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was PKR 6,593.61 million compared to PKR 6,079.61 million a year ago. Net loss was PKR 345.21 million compared to net income of PKR 363.89 million a year ago. Basic loss per share from continuing operations was PKR 2.95 compared to basic earnings per share from continuing operations of PKR 3.11 a year ago.
For the nine months, sales was PKR 20,807.87 million compared to PKR 18,002.45 million a year ago. Net loss was PKR 67.93 million compared to net income of PKR 1,642.62 million a year ago. Basic loss per share from continuing operations was PKR 0.58 compared to basic earnings per share from continuing operations of PKR 14.03 a year ago.